MX2013011854A - Compuestos de pirazol[3,4-b]piridina tri- y tetraciclica como agentes antineoplasicos. - Google Patents

Compuestos de pirazol[3,4-b]piridina tri- y tetraciclica como agentes antineoplasicos.

Info

Publication number
MX2013011854A
MX2013011854A MX2013011854A MX2013011854A MX2013011854A MX 2013011854 A MX2013011854 A MX 2013011854A MX 2013011854 A MX2013011854 A MX 2013011854A MX 2013011854 A MX2013011854 A MX 2013011854A MX 2013011854 A MX2013011854 A MX 2013011854A
Authority
MX
Mexico
Prior art keywords
same
antineoplastic agent
tetracyclic
pyrazolo
tri
Prior art date
Application number
MX2013011854A
Other languages
English (en)
Inventor
Remi Rabot
Karim Bedjeguelal
El Bachir Kaloun
Phillippe Schmitt
Nicolas Rahier
Patrice Mayer
Emmanuel Fournier
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2013011854A publication Critical patent/MX2013011854A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems

Abstract

La presente invención se refiere a compuestos de la siguiente fórmula general (I) (ver Fórmula) y a sales farmacéuticamente aceptables del mismo, los tautómeros del mismo, los estereoisómeros o mezcla de estereoisómeros en cualesquiera proporciones del mismo, tal como una mezcla de enantiómeros, en especial una mezcla racémica, así como también métodos para preparar el mismo y usos del mismo, en especial como un agente antineoplásico.
MX2013011854A 2011-04-12 2012-04-12 Compuestos de pirazol[3,4-b]piridina tri- y tetraciclica como agentes antineoplasicos. MX2013011854A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1153200A FR2974088A1 (fr) 2011-04-12 2011-04-12 Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux
PCT/EP2012/056637 WO2012140114A1 (en) 2011-04-12 2012-04-12 Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent

Publications (1)

Publication Number Publication Date
MX2013011854A true MX2013011854A (es) 2013-11-01

Family

ID=44512344

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011854A MX2013011854A (es) 2011-04-12 2012-04-12 Compuestos de pirazol[3,4-b]piridina tri- y tetraciclica como agentes antineoplasicos.

Country Status (16)

Country Link
US (1) US9085575B2 (es)
EP (1) EP2697222A1 (es)
JP (1) JP5972964B2 (es)
KR (1) KR20140023341A (es)
CN (1) CN103534254B (es)
AR (1) AR085987A1 (es)
AU (1) AU2012241891B2 (es)
BR (1) BR112013026355A2 (es)
CA (1) CA2832704A1 (es)
FR (1) FR2974088A1 (es)
HK (1) HK1190397A1 (es)
MX (1) MX2013011854A (es)
RU (1) RU2013148922A (es)
TW (1) TWI560187B (es)
WO (1) WO2012140114A1 (es)
ZA (1) ZA201307783B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
DK3176170T3 (en) 2012-06-13 2019-01-28 Incyte Holdings Corp SUBSTITUTED TRICYCLIC RELATIONS AS FGFR INHIBITORS
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
ES2893725T3 (es) 2013-04-19 2022-02-09 Incyte Holdings Corp Heterocíclicos bicíclicos como inhibidores del FGFR
ES2714576T3 (es) 2014-07-04 2019-05-29 Qilu Pharmaceutical Co Ltd Oxido de arilfósforo y sulfuro de arilfósforo espirocíclicos
CN104447736B (zh) * 2014-10-14 2016-06-08 雅安职业技术学院 一种veranamine的合成方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9974784B2 (en) * 2015-01-21 2018-05-22 The Texas A&M University System Inhibitors of activin-like receptor kinases
CN107438607B (zh) 2015-02-20 2021-02-05 因赛特公司 作为fgfr抑制剂的双环杂环
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
CN116710453A (zh) * 2020-08-07 2023-09-05 璧辰医药技术股份有限公司 激酶抑制剂及其用途
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872014B2 (en) * 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
JP5016601B2 (ja) * 2005-08-16 2012-09-05 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
CN101525497B (zh) * 2008-03-06 2012-07-04 中国科学院理化技术研究所 吡唑啉吡啶并苯并香豆素荧光染料衍生物及其合成方法和用途
US20100113415A1 (en) * 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer

Also Published As

Publication number Publication date
FR2974088A1 (fr) 2012-10-19
TWI560187B (en) 2016-12-01
EP2697222A1 (en) 2014-02-19
WO2012140114A1 (en) 2012-10-18
US20140031362A1 (en) 2014-01-30
RU2013148922A (ru) 2015-05-20
KR20140023341A (ko) 2014-02-26
AU2012241891B2 (en) 2016-06-16
CN103534254A (zh) 2014-01-22
JP5972964B2 (ja) 2016-08-17
CN103534254B (zh) 2015-11-25
BR112013026355A2 (pt) 2016-12-27
ZA201307783B (en) 2015-01-28
AU2012241891A1 (en) 2013-10-31
TW201247665A (en) 2012-12-01
HK1190397A1 (zh) 2014-07-04
AR085987A1 (es) 2013-11-13
JP2014510774A (ja) 2014-05-01
US9085575B2 (en) 2015-07-21
CA2832704A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
MX2013011854A (es) Compuestos de pirazol[3,4-b]piridina tri- y tetraciclica como agentes antineoplasicos.
GEP201706774B (en) Heterocyclyl compounds
MX2013007148A (es) 2-arilimidazo[1,2-b]piridazina, 2-fenilimidazo[1,2-a]pirimidina, y derivados de 2-fenilimidazo[1.2-a]pirazina.
TN2015000034A1 (en) Derivatives of azaindazole or diazaindazole type for treating pain
MY170878A (en) [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
MX336214B (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
MX2016006336A (es) Compuestos pirazolopirimidina.
MX2013005445A (es) Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
MX2014014229A (es) Pirrolidina-2-carboxamidas sustituidas.
MX346248B (es) Derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas de los agonistas del receptor canabinoide 2.
AU2012213775A8 (en) 7-azaindole derivatives
EA201300620A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ JAK
PH12014501542B1 (en) Substituted pyrrolidine -2- carboxamides
IL228158A0 (en) History of 7,6-dihydro-pyrazolo[5,1-a]pyrazine-4-ylamine used as betascartase inhibitors
PH12014501258A1 (en) Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
WO2013004995A8 (en) Pyrimidinone compounds and their use
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2014000635A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak.
MX340574B (es) Imidazo pirazinas.
AU2012342891A8 (en) 3-Cyanoaryl-1H-pyrrolo[2.3-b]pyridine derivatives
WO2014062838A3 (en) Pkm2 modulators and methods for their use
MX2014002949A (es) Compuesto de imidazopiridina, composiciones y metodos de uso.
WO2014053968A8 (en) Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
PH12015500061A1 (en) Method for preparing substituted triazolopyridines

Legal Events

Date Code Title Description
FA Abandonment or withdrawal